EQUINOXE study: Impact of relational cohesion and sexuality on the quality of life of patients treated with gonadotropin-releasing hormone agonist for prostate cancer.

To measure the effect of dyadic adjustment on changes in patients' quality of life when initiating treatment with gonadotropin-releasing hormone (GnRH) agonist. A prospective, multicenter, longitudinal, and non-interventional study (NCT02630641) that included patients with prostate cancer starting GnRH agonist therapy, and their partners, in 157 centers in France. Data were collected at inclusion and after 6 months of treatment on quality of life (WHOQOL-BREF), disease perception (B-IPQ), disease symptoms (QLQ-PR25), and perception of cohesion within the couple (dyadic adjustment, DAS-16). The Full Analysis Set included 492 patients (median age [Q1;Q3]: 74 [68;80] years). An improvement of the quality of life (defined as the improvement of at least one of the four dimensions of WHOQOL-BREF) was reported in 290/434 (67%) patients between baseline and follow-up. Quality of life was better at baseline and follow-up in patients with good cohesion within the couple than in those with medium or poor cohesion. Factors associated with improvement in quality of life of patients were the following: initial presence of QLQ-PR25 hormonal treatment-related symptoms (OR [95% CI]: 3.00 [1.46, 6.17]) suggesting testosterone deficiency symptoms at baseline and initial low level (2.04 [1.12, 3.72]) or absence of sexual activity (2.23 [1.11, 4.50]) before GnRH agonist initiation. Men with the greatest improvement in quality of life after initiating hormone therapy were those with, at baseline, testosterone deficiency symptoms (identified by QLQ-PR25 treatment-related symptoms score) or no/low sexual activity. Cohesion within the couple was not confirmed as an influence on the evolution of quality of life.

Informations de copyright

© 2021 The Authors. BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company.

Déclaration de conflit d'intérêts

Stéphane Droupy: Ipsen, Menarini, Majorelle, AMS, Intuitive Surgical, Sanofi, Pierre Fabre, Takeda, Ferring. Marie‐Hélène Colson: Allergan, Astellas, Astra‐Zeneca, Bayer santé familiale, Biopharm, Boston, Bouchara‐Recordati, Ferring SA, Genévrier, Ipsen, Lilly SA, Majorelle, Menarini, Novartis, Pfizer santé de la famille. Aurélien Descazeaud: Bouchara Recordati, Ipsen, Sanofi, Pierre Fabre, Takeda. Nathalie Pello‐Leprince‐Ringuet and Valérie Perrot are employees of Ipsen.